Oral chronic graft-versus-host disease in pediatric patients after hematopoietic stem cell transplantation

被引:47
|
作者
Treister, NS
Woo, SB
O'Holleran, EW
Lehmann, LE
Parsons, SK
Guinan, EC
机构
[1] Harvard Univ, Sch Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA
[4] Tufts Univ, Sch Med, Dept Med & Pediat, Boston, MA 02111 USA
关键词
graft-versus-host disease; hematopoietic stem cell transplantation; pediatric patients; oral lesions;
D O I
10.1016/j.bbmt.2005.06.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic graft-versus-host disease (cGVHD) is a serious and potentially life-threatening complication of hematopoietic stem cell transplantation. This study, which is the largest single-center series of oral disease in pediatric patients with cGVHD, describes the oral findings in 49 consecutive patients seen in a pediatric multidisciplinary cGVHD clinic. All consecutive patients seen at the multidisciplinary pediatric hematopoietic stem cell transplantation/cGVHD clinic at the Dana-Farber Cancer Institute (Boston, MA) from July 2001 through October 2003 were included in this study. Subjective and objective assessments of mucosal, salivary gland, and sclerotic pathology were performed for each patient, and specific therapy was initiated when indicated. Oral mucosal cGVHD was identified in 22 (45%) of 49 patients. Only 4 (8%) of 49 patients reported mouth pain, and all patients reported being able to eat well. All patients who required specific therapy for their oral mucosal cGVHD (45%) were already taking at least 1 immunomodulatory agent; however, efficacy of treatment was difficult to assess because of inconsistent follow-up periods. Subjective and objective salivary gland and sclerotic disease were observed far less often. Oral mucosal pathology is common in these patients, and appropriate diagnosis and management of oral lesions is critical to reduce patient morbidity and to improve quality of life. The apparent lack of salivary gland involvement was notable. Developing validated age-appropriate evaluation strategies and identifying effective treatment guidelines will be invaluable in the future management of these patients. (c) 2005 American Society for Blood and Marrow Transplantation.
引用
收藏
页码:721 / 731
页数:11
相关论文
共 50 条
  • [41] Graft-versus-host disease induced by tisagenlecleucel in patients after allogeneic stem cell transplantation
    Gabelli, Maria
    Marks, David I.
    Sharplin, Kirsty
    Lazareva, Arina
    Mullanfiroze, Khushnuma
    Farish, Susan
    Burridge, Saskia
    Velangi, Mark
    Rampling, Dyanne
    Mozayani, Behrang
    Chiesa, Robert
    Lucchini, Giovanna
    Samarasinghe, Sujith
    Bartram, Jack
    Ghorashian, Sara
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 195 (05) : 805 - 811
  • [42] Altered functional status of the hypothalamic dopaminergic tone in patients with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation:: A pilot study
    Parra, A
    Ramírez-Peredo, J
    Hidalgo, R
    Morales-Toquero, A
    Velásquez-Ramírez, G
    Ruiz-Argüelles, A
    Ruiz-Argüelles, GJ
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (05) : 566 - 572
  • [43] Myeloablative haploidentical hematopoietic stem cell transplantation using basiliximab for graft-versus-host disease prophylaxis
    Huang, Rui
    Tu, Sanfang
    Deng, Lan
    Kang, Qian
    Song, Chaoyang
    Li, Yuhua
    HEMATOLOGY, 2015, 20 (06) : 313 - 319
  • [44] Surfactant protein D is associated with pulmonary manifestations of chronic graft-versus-host disease following hematopoietic stem cell transplantation
    Krarup, Anne Mols
    Kielsen, Katrine
    Uhlving, Hilde Hylland
    Steffensen, Rudi
    Sorum, Maria Ebbesen
    Nielsen, Kim Gjerum
    Buchvald, Frederik F.
    Sorensen, Grith L.
    Mueller, Klaus Gottlob
    PEDIATRIC PULMONOLOGY, 2024, 59 (04) : 1103 - 1107
  • [45] Mycophenolate mofetil for treatment of steroid-refractory acute graft-versus-host disease after pediatric hematopoietic stem cell transplantation
    Inagaki, Jiro
    Kodama, Yuichi
    Fukano, Reiji
    Noguchi, Maiko
    Okamura, Jun
    PEDIATRIC TRANSPLANTATION, 2015, 19 (06) : 652 - 658
  • [46] Elevation of tacrolimus concentration after administration of methotrexate for treatment of graft-versus-host disease in pediatric patients received allogeneic hematopoietic stem cell transplantation
    Chiaki Inoue
    Takehito Yamamoto
    Hiroshi Miyata
    Hiroshi Suzuki
    Tappei Takada
    Journal of Pharmaceutical Health Care and Sciences, 9
  • [47] Thalidomide in Chronic Graft-versus-Host Disease after Stem Cell Transplantation: Effects on Quality of Life
    Steve Miller
    Shalini Sharda
    James Rodrigue
    Paulette Mehtaa
    International Journal of Hematology, 2002, 76 : 365 - 369
  • [48] Salivary Proteomic Analysis and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
    Chiusolo, Patrizia
    Giammarco, Sabrina
    Fanali, Chiara
    Bellesi, Silvia
    Metafuni, Elisabetta
    Sica, Simona
    Iavarone, Federica
    Cabras, Tiziana
    Messana, Irene
    Leone, Giuseppe
    Castagnola, Massimo
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (06) : 888 - 892
  • [49] Thalidomide in chronic graft-versus-host disease after stem cell transplantation: Effects on quality of life
    Miller, S
    Sharda, S
    Rodrigue, J
    Mehta, P
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2002, 76 (04) : 365 - 369
  • [50] Cutaneous graft-versus-host disease after hematopoietic stem cell transplant - a review
    Villarreal Villarreal, Cesar Daniel
    Salas Alanis, Julio Cesar
    Jaime Perez, Jose Carlos
    Ocampo Candiani, Jorge
    ANAIS BRASILEIROS DE DERMATOLOGIA, 2016, 91 (03) : 336 - 343